Tuesday, October 3, 2006
INC Research, a Raleigh, N.C.-based contract research organization (CRO),has acquired Pharmaceutical Research (PRC), a late stage–focused CRO based in Hatboro, Penn. INC was actively searching for an opportunity to grow in the area of late stage trials. The acquisition allows INC to expand its phase IIIb/IV capabilities. About 90% of INC’s business is in the phase I to III market, while 70% of the trials that PRC services are in phase IIIb/IV. “PRC has a strong reputation in that area, and so they were an obvious choice for us to talk to. It was also culturally similar with some great goals for growth,” John Potthoff, president and chief operating officer, INC Research told CWWeekly.
Alquest, a medical device focused contract research organization (CRO) based in Minneapolis, Minn., has launched services in India. The company claims to be the first such CRO to expand medical device offerings into the emerging India trials market. Medical device companies are particularly afflicted by challenging patient recruitment rates, and Alquest feels many companies will head to India to shave costs.
Clinical research in Latin America has grown significantly over the past 10 years but obstacles to continued growth still exist. In our first-ever survey of investigative sites in Latin America, we at Thomson CenterWatch found that bottlenecks at the site level continue to hinder growth of clinical research in the region as researchers strive to improve the system.
Hot Latin American Clinical Research Market Will Moderate
Helping to quell a storm of a controversy, the FDA has issued new guidelines describing the circumstances when informed consent can be waived for clinical trials in emergency or ambulatory settings. It’s a big issue. Informed consent is a ‘sacred cow’ in today’s clinical trial industry, and rightly so.
Hesperion Acquires TouchStone Research in Maryland